Clinical effect of loading dose and high maintenance dose of atorvastatin in patients with acute coronary syndrome after interventional treatment
DONG Li-jun
HONG Zi-hui
Abstract：Objective To observe the clinical effect of loading dose and high maintenance dose of atorvastatin in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods ACS patients (n=80) were chosen from Jan. 2012 to Jun. 2013, and randomly divided into control group and observation group (eachn=40). All patients were given routine drug therapy and PCI, and then control group was given atorvastatin (20 mg/d) after PCI, and observation was given atorvastatin (80 mg) 1 d after PCI, atorvastatin in decreased dose (40 mg/d) 2 d after PCI and atorvastatin (20 mg/d) 1 m after PCI. The levels of low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), triglyceride (TG), total cholesterol (TC), N-terminal pro brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), interleukin-18 (IL-18), interleukin-6 (IL-6), high sensitivity C-reactive protein (hs-CRP), endothelin-1 (ET-1) and nitric oxide (NO) were detected in 2 groups, and the incidence of major adverse cardiovascular events (MACE) was recorded within 1 y after discharged from hospital.Results After treatment for 1 m, the levels of LDL-C, TG, TC and NT-proBNP decreased and HDL-C increased in 2 groups (allP<0.05). Compared with control group after treatment, the levels of LDL-C, TG, TC and NT-proBNP decreased and HDL-C and LVEF increased in observation group (allP<0.05). After treatment for 1 m, the levels of IL-18, IL-6, hs-CRP and ET-1 decreased and NO increased in 2 groups (allP<0.05). Compared with control group after treatment, the levels of IL-18, IL-6, hs-CRP and ET-1 decreased and NO increased in observation group (allP<0.05). Compared with control group, the incidence of MACE decreased in observation group (75%vs. 10%,P<0.01).Conclusion Atorvastatin in loading dose and high maintenance dose can effectively recover the levels of blood fat and inflammatory factors, improve left heart function and reduce MACE incidence compared with routine therapy in ACS patients.
Keywords：AtorvastatinAcute coronary syndromePercutaneous coronary interventionLoading doseHigh maintenance dose
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 474-476,479 )